Clinical Trial Update: A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of benralizumab in chronic spontaneous urticaria terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: TERMINATED | Results posted: 2024-03-13